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Feline immunodeficiency virus (FIV) causes AIDS-like symptoms in infected cats. Concanavalin A (ConA)-
stimulated peripheral blood mononuclear cells (PBMC) from chronically FIV strain PPR-infected cats readily
expressed FIV. In contrast, when PBMC from these animals were stimulated with irradiated, autologous
antigen-presenting cells (APC), at least a 10-fold drop in viral production was observed. In addition to
FIV-specific cytotoxic T lymphocytes, anti-FIV activity was demonstrated in the cell-free supernatants of
effector T lymphocytes stimulated with APC. The FIV-suppressive activity was induced from APC-stimulated
PBMC of either FIV-infected or uninfected cats but not from ConA-stimulated PBMC. Suppression of FIV
strain PPR replication was observed for both autologous and heterologous feline PBMC, was dose dependent,
and demonstrated cross-reactivity and cell specificity. It was also demonstrated that the anti-FIV activity
originated from CD81 T lymphocytes and was mediated by a noncytolytic mechanism.
Feline immunodeficiency virus (FIV) is a T-lymphotropic len-
tivirus in the family Retroviridae (35). Infection of cats with FIV
causes transient fever, leukopenia, generalized lymphadenop-
athy, and finally an immunodeficiency-like syndrome, such as
stomatitis, upper respiratory disease, neurological disease, or
lymphoma (16, 35, 50). FIV infects both CD41 and CD81 T
lymphocytes (9) and induces the characteristic inversion of
CD41/CD81 T-cell ratios (1, 16, 31, 42). As with human im-
munodeficiency virus (HIV) infection in humans (7, 26, 46),
following infection of cats with FIV, cytolytic and noncytolytic
cellular immune mechanisms are suggested to participate in
the control of virus replication in vivo (3, 10, 23, 40).
Major histocompatibility complex-restricted FIV- and HIV-
specific cytotoxic T lymphocytes (CTL) are predominantly
composed of CD81 T lymphocytes (7, 40). CTL-mediated cel-
lular immunity has been suggested to control the initial viral
infection prior to the production of virus-specific antibody (3,
26). It has also been suggested that CTL activity correlates with
disease progression in HIV-infected patients (20, 37). HIV
type 1-infected individuals exerting active CTL responses
showed rapidly reduced plasma viremia and virus replication.
In contrast, patients with low or undetectable CTL responses
did not show control of virus replication and progressed to the
AIDS state. FIV-infected cats or cats vaccinated with inacti-
vated FIV have been shown to produce FIV-specific CTL
responses (3, 18, 28, 41, 44). FIV-specific CTL also are sug-
gested to participate in establishing protective immunity in cats
(21, 45).
CD81 T lymphocytes from HIV-infected subjects have also
been shown to inhibit viral replication without cytotoxicity in
CD81 T-cell-depleted peripheral blood mononuclear cells
(PBMC) (46). Furthermore, this noncytolytic mechanism
could be reconstituted following the addition of CD81 T cells
to infected CD41 T lymphocytes (48). The soluble anti-HIV
factor present in cell-free supernatants of CD81 T cells was
later designated CD81 T-cell antiviral factor (29, 47). The
presence of similar soluble antiviral factors was demonstrated
for CD81 T cells of simian immunodeficiency virus-infected
African green monkeys and HIV type 2-infected baboons (5,
17). In addition to the uncharacterized T-cell antiviral factor,
interleukin 16 (IL-16) and several chemokines have been iden-
tified as HIV-suppressive factors (2, 6, 13, 33). It appears that
the antiviral activities derived from CD81 cells consist of mul-
tiple independent factors (38, 39). Like the cytolytic antiviral
activity of CTL, the noncytolytic antiviral activities of CD81 T
cells were associated with the clinical stages of HIV and FIV
infections (4, 10). CD81 T lymphocytes from HIV-infected
long-term survivors very efficiently suppressed HIV replica-
tion, but CD81 T cells from AIDS patients did not inhibit viral
replication (4). Some infected cats, showing no evidence of
seroconversion or FIV infection, had strong CD81 T-cell-me-
diated activity that readily inhibited FIV replication (10).
In the present study, we demonstrated that PBMC with
consistent FIV-specific CTL activity produced an anti-FIV sol-
uble factor(s) following stimulation with FIV-infected and ir-
radiated antigen-presenting cells (APC). The anti-FIV fac-
tor(s) suppressed viral replication in PBMC by a noncytolytic
mechanism.
MATERIALS AND METHODS
Experimental animals. Specific-pathogen-free cats purchased from Harlan
Sprague-Dawley, Madison, Wis., or Liberty Laboratories, Liberty Corner, N.J.,
were serologically negative for feline leukemia virus. Cats were housed in an
specific-pathogen-free environment at the Laboratory Animal Research and
Resources Facility, Texas A&M University, College Station. Cats AUO2, AUO3,
AWF1, AZV2, OLQ5, E238, E284, 306, and 308 were chronically infected with
FIV strain PPR (FIV-PPR). Cats AUS3, E266, OAE5, OLM6, and OLQ4, sham
inoculated with saline solution, were used as negative control cats.
Virus. FIV-PPR was propagated in feline PBMC, and FIV strain Pet (FIV-
Pet) was propagated in Crandell feline kidney (CrFK) cells (36). After 7 to 10
days of infection, virus replication was evaluated with an FIV capsid antigen
(p24) detection enzyme-linked immunosorbent assay (ELISA) kit (IDEXX,
Portland, Maine). Supernatants with an optical density (OD) of more than 3.5
were collected, and these stocks were stored at 270°C.
Cell culture. Feline PBMC were isolated from EDTA (K3)-treated whole
blood by Histopaque-1077 (Sigma, St. Louis, Mo.) density gradient centrifuga-
tion. PBMC were cultured as described previously with RPMI 1640 (Gibco BRL,
Grand Island, N.Y.) supplemented with 10% fetal bovine serum (FBS), 50 mg of
gentamicin (Gibco BRL) per ml, 5 3 1025 M 2-mercaptoethanol (Gibco BRL),
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2 mM L-glutamine (Gibco BRL), and 100 U of human recombinant IL-2 (hr
IL-2) (Collaborative Biomedical Products, Bedford, Mass.) per ml (40). Cells
were grown at 37°C in a humidified atmosphere of 5% CO2. The medium was
changed every 3 to 4 days. FIV replication in the culture supernatants was
determined by detection of FIV capsid antigen with the ELISA kit. Phenotypes
of T cells were analyzed by flow cytometry as described previously (28). FIV-
Pet-infected CrFK cells were cultured in complete Dulbecco modified Eagle
medium supplemented with 10% FBS and 50 mg of gentamicin per ml.
Stimulation of effector cells. Feline PBMC were stimulated with 5 mg of
concanavalin A (ConA) mitogen per ml for 3 days. The stimulated lymphoblas-
toid cells were infected with 0.5 ml of FIV-PPR stock for 30 min at 37°C and
cultured in complete RPMI 1640. After 6 days of culturing, virus infection was
verified with the capsid antigen ELISA kit. These FIV-infected cells were used
as APC for the stimulation of effector cells and as target cells in CTL assays.
FIV-infected cells were inactivated by irradiation (10,000 rads from a 60Co
source) and used as autologous APC by coculturing with effector cells (40).
Effector cells (106 cells/ml) were stimulated every 3 to 4 days for the first 10 days
in the presence of only APC (1 3 105 to 2 3 105 cells/ml), without ConA or hr
IL-2. On day 10, viable effector cells were isolated by Histopaque-1077 gradient
centrifugation, resuspended in complete RPMI 1640 supplemented with 100 U
of hr IL-2 per ml, and cultured with APC for an additional 4 days. After 2 weeks
of stimulation with APC, CTL responses of effector cells were determined with
FIV-infected target cells.
Cytotoxicity assay. CTL assays were performed as previously described but
with modifications (28, 40). Viable FIV-infected cells were isolated by His-
topaque-1077 gradient centrifugation. Purified FIV-infected cells (106 for each
group) were washed twice with complete RPMI 1640, and the supernatants were
removed from the cell pellets. The cells were resuspended in 100 ml of complete
RPMI 1640, and 5 mCi of indium-111 oxine (Medi-Physics Amersham, Inc., San
Antonio, Tex.) was added to each cell group. The cells were incubated at 37°C for
30 min. 111In-labeled cells were washed four times with complete RPMI 1640 and
resuspended in 10 ml of complete RPMI 1640. CTL assays were done in tripli-
cate at various effector/target (E/T) ratios. Target cells (5 3 103) in 100 ml of
complete RPMI 1640 were placed in each well of V-bottom 96-well tissue culture
plates (Costar, Cambridge, Mass.). Effector cells (100 ml) were added to each
well containing target cells at the appropriate E/T ratio. Spontaneous release was
measured for wells receiving 100 ml of complete RPMI 1640, and maximum
release was measured for wells receiving 100 ml of 3% Triton X-100 instead of
effector cells. The plates were centrifuged at 125 3 g for 4 min, incubated at 37°C
for 4 h, and then centrifuged at 450 3 g for 5 min. A 100-ml portion of super-
natant was taken from each well, and counts per minute were counted with a
gamma radiation counter (Cobra Auto-Gamma Counter; Packard Instrument
Company, Meriden, Conn.). The percent specific cytotoxicity for triplicate sam-
ples was calculated as follows: percent cytotoxicity 5 [(experimental release 2
spontaneous release)/(maximum release 2 spontaneous release)] 3 100. The
percentage of spontaneous release/maximum release was less than 20%.
Culture supernatants from effector cells. Cell-free supernatants were collected
from APC-stimulated effector cells induced from PBMC of FIV-PPR-infected
and uninfected cats. The supernatants were centrifuged at 25,000 rpm for 2 h
(Beckman Instruments, Palo Alto, Calif.) to pellet the residual viral particles (11)
before passage through 0.2-mm-pore-size filters. The amount of FIV capsid
antigen (p24) remaining in the supernatants after ultracentrifugation was negli-
gible (data not shown). The supernatants were stored at 270°C.
Phenotype enrichment. The panning method was used for enrichment of
CD81 and CD41 T cells from freshly isolated PBMC or APC-stimulated effector
cells (49). Briefly, 107 PBMC were incubated on ice for 30 min with 2 ml of
phosphate-buffered saline (PBS) containing 10 mg of mouse anti-cat CD41 or
anti-cat CD81 monoclonal antibody (Southern Biotechnology Associates, Inc.,
Birmingham, Ala.) per ml. The cells were washed twice, resuspended in 4 ml of
PBS containing 1% FBS, and incubated on a petri dish coated with goat anti-
mouse immunoglobulin G monoclonal antibody (Southern Biotechnology Asso-
ciates) for 2 h at 4°C. The goat anti-mouse immunoglobulin G-coated petri dish
was prepared by incubating 10 mg of monoclonal antibody per ml in PBS over-
night at room temperature and washing with cold PBS. Plates were incubated
with PBS containing 1% FBS prior to use to prevent nonspecific binding of
PBMC. Unbound CD81 or CD41 cells were collected and cultured in complete
RPMI 1640. The purity of depleted cells obtained by this method was greater
than 95%, as determined by flow cytometry (data not shown).
Human chemokines. Human recombinant b-chemokines, MIP-1a, MIP-1b,
and RANTES (PeproTech, Inc., Rocky Hill, N.J.), were diluted in complete
RPMI 1640 at a concentration of 1,000 ng/ml. A human recombinant a-chemo-
kine, SDF-1a (PeproTech), was diluted in complete RPMI 1640 at a concentra-
tion of 4,000 ng/ml. The diluted chemokines were added to FIV-PPR-infected
feline PBMC at a 1:1 ratio of cell culture medium to chemokine solution, and
their suppressive activities were compared with that of the supernatant of APC-
stimulated feline effector cells.
Statistical analysis. The differences in FIV replication and cell viability be-
tween infected control cells and anti-FIV factor(s)-treated cells were analyzed
with a two-tailed Student t test (32). Statistical significance was set at a P value
of ,0.05 or, in general, 65% or less virus expression than in untreated controls.
RESULTS
Kinetics of FIV replication in PBMC. FIV infects both feline
CD41 and feline CD81 T cells (9, 14, 15). In this report, the
kinetics of FIV-PPR isolation were determined with ConA-
stimulated, unfractionated PBMC and CD41 and CD81 T
cells from experimentally FIV-PPR-infected cats. FIV-PPR
could be isolated from PBMC of FIV-PPR-infected cats 306
and 308 (Fig. 1). No viral antigen was detected in cultured
PBMC of uninfected cat AUS3 (Fig. 1). However, in cultured
PBMC of both FIV-PPR-infected cats, FIV replication could
be detected within 9 to 12 days of culturing. The production of
FIV antigen rapidly increased until day 16 of culturing, the last
day examined. This study demonstrated that FIV-PPR could
be isolated from ConA-stimulated, unfractionated PBMC of
infected cats even without the removal of CD81 T lympho-
cytes. FIV-PPR replication in cultured CD41 and CD81 T
cells was examined to confirm the cell tropism of FIV. The
CD41 T lymphocytes of cat 306 produced 5.8-fold more FIV
than the CD81 T lymphocytes of the same cat after 15 days of
culturing (Fig. 2). In contrast, the CD81 T lymphocytes of cat
308 produced more FIV than the CD41 T lymphocytes of the
same cat (Fig. 2). In addition, both CD41 and CD81 T cells of
cat 308 reproducibly expressed more viral antigen than those
of cat 306 under identical culture conditions.
Development of FIV-specific CTL. The presence of FIV-
specific CTL was verified by use of PBMC from FIV-PPR-
infected cats. PBMC of infected cats 306 and 308 and unin-
fected cats E266 and AUS3 were stimulated for 2 weeks with
autologous, irradiated FIV-PPR-infected cells. FIV-infected
autologous PBMC were used as target cells. Antigen-stimu-
lated effector cells of FIV-infected cats 306 and 308 demon-
strated 30% lysis of target cells at an E/T ratio of 100:1 (Fig.
3A) and 15% lysis of target cells at an E/T ratio of 80:1 (Fig.
3B), respectively. In contrast, there was no FIV-specific killing
in CTL assays with antigen-stimulated PBMC from uninfected
cats E266 (Fig. 3A) and AUS3 (Fig. 3B).
Antigen-stimulated effector cells produced an anti-FIV fac-
tor(s). As verified in Fig. 1 and 2, the stimulation of PBMC of
FIV-infected cats with ConA mitogen induced virus produc-
tion. However, as expected, the stimulation of PBMC with
APC induced major histocompatibility complex-restricted ac-
tivation of CD81 T cells, such as the CTL demonstrated in Fig.
FIG. 1. Kinetics of FIV replication in PBMC of infected cats. PBMC of
uninfected and FIV-infected cats were cultured at a concentration of 5 3 105/ml
in RPMI-1640 supplemented with 100 U of hr IL-2 per ml after ConA stimula-
tion for the first 3 days. The culture supernatants were harvested on the indicated
days of culturing. FIV replication was measured by use of an FIV capsid antigen
(p24) ELISA. Data are for uninfected cat AUS3 (diamonds) and FIV-infected
cats 306 (circles) and 308 (squares).
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3. Virus production in PBMC stimulated with APC was further
investigated. PBMC of infected cats were stimulated with au-
tologous, irradiated FIV-infected cells for 3 weeks, and the
culture supernatants of stimulated effector cells were collected
every 3 or 4 days. In order to study suppressive activity for
FIV-PPR replication, the collected supernatants were added
to autologous, ConA-stimulated PBMC. ConA-stimulated
PBMC readily produced virus after day 12 of culturing, and the
amount of virus continued to increase until day 21 of culturing
(Fig. 4). After 21 days, virus expression rapidly decreased. In
contrast, APC-stimulated PBMC (effector cells) from infected
cat 308 produced very little virus (Fig. 4). FIV-PPR replication
in APC-stimulated PBMC was inhibited 90% compared with
that in ConA-stimulated PBMC following 21 days of culturing
without APC. Although the growth rate of APC-stimulated
cells for the first 7 days of culturing was slower than that of
mitogen-stimulated cells, both types of cells had similar growth
rates following the addition of IL-2 to APC-stimulated cells
from day 8 to day 25 of culturing (data not shown). The culture
supernatants of effector cells also demonstrated inhibition of
FIV-PPR replication in autologous, infected ConA-stimulated
PBMC (Fig. 4). Virus production from cells cultured with
supernatants of effector cells was suppressed 89% compared
with that from ConA-stimulated control cells. The growth rate
of cells cultured with supernatant was the same as that of
control cells cultured without supernatant (data not shown).
Although in this experiment the removal of APC from effector
cells on day 21 was followed by an increase of viral expression,
in additional experiments, the effects of removing APC from
effector cells on viral expression were variable (data not
shown).
Secretion of a soluble FIV-suppressive factor(s) from anti-
gen-stimulated PBMC of FIV-infected and uninfected cats. In
order to confirm that FIV replication could be suppressed by
CTL and by the anti-FIV factor(s) in the cell culture superna-
tants, T-lymphocyte responses were examined with additional
uninfected and FIV-infected cats. Cytolytic activity of effector
cells from uninfected cats was always less than 1.5%. Although
the CTL responses were often low, FIV-specific responses
were consistently detected in infected cats (Table 1), suggest-
ing that cytotoxic cellular immune responses are functional in
the elimination of virus-infected cells. When FIV-infected cells
were cultured with supernatants collected from APC-stimu-
lated effector cells, FIV-PPR replication was inhibited not only
by the supernatants of APC-stimulated effector cells from FIV-
infected cats but also by the supernatants from uninfected cats
(Table 1). In experiment 1, supernatants of stimulated effector
cells collected from cats AUO2, AUO3, AZV2, and OLQ5
were shown to significantly suppress viral infection in the
PBMC of cat 308. The supernatant of APC-stimulated cells
from uninfected cat OLQ4 also demonstrated strong suppres-
sive activity (68% inhibition) for FIV replication. In experi-
ment 2, with three additional FIV-PPR-infected cats, the su-
pernatant from APC-stimulated PBMC of one infected cat,
AWF1, demonstrated strong suppression of virus replication.
However, the supernatants from APC-stimulated cells of two
infected cats, E238 and E284, did not significantly inhibit virus
replication. These results confirmed that FIV-PPR replication
could be inhibited by a soluble suppressive factor(s) present in
the effector cell culture supernatants collected from either
FIV-infected or uninfected cats. The soluble anti-FIV fac-
tor(s)-mediated inhibitory mechanism was not cytotoxic, be-
FIG. 2. Kinetics of FIV replication in CD41 and CD81 T lymphocytes of
infected cats. CD41 and CD81 T cells were prepared by the panning method and
stimulated with ConA for the first 3 days. Cells were cultured in complete
RPMI-1640 supplemented with 100 U of hr IL-2 per ml at a concentration of 5 3
105/ml. FIV replication was measured in the culture supernatants by an ELISA.
Data are for FIV-infected cat 306 CD41 (closed circles) and CD81 (open
circles) T cells and FIV-infected cat 308 CD41 (closed squares) and CD81 (open
squares) T cells.
FIG. 3. FIV-specific CTL activities in infected cats. PBMC of FIV-infected
and uninfected cats were stimulated in vitro with APC for 2 weeks and used as
effector cells. Their cytotoxic activities were measured with 111In-labeled autol-
ogous FIV-infected target cells. (A) FIV-infected cat 306 (circles) and uninfected
cat E266 (triangles). (B) FIV-infected cat 308 (squares) and uninfected cat
AUS3 (triangles).
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cause the percent viabilities of the control cells and the cells
cultured with supernatants were not statistically different (P,
.0.05).
Suppression of FIV replication by the supernatants of an-
tigen-stimulated PBMC but not by the supernatants of ConA-
stimulated PBMC. Since FIV-PPR-suppressive activity was
demonstrated in the supernatants from APC-stimulated
PBMC of uninfected cat OLQ4 (Table 1), additional unin-
fected cats were used as sources of inducible T lymphocytes.
All supernatants collected from APC-stimulated uninfected
and FIV-infected cat PBMC strongly inhibited FIV-PPR rep-
lication in the infected heterologous cells (P, ,0.05) (Table 2).
However, supernatants obtained from ConA-stimulated PBMC
did not demonstrate suppression of FIV-PPR replication (P,
.0.05) (Table 2). This result suggested that only antigen-spe-
cific stimulation of either FIV-infected or uninfected cat
PBMC could induce the secretion of the soluble anti-FIV
factor(s) into the supernatants.
FIG. 4. Suppression of FIV replication in antigen-stimulated effector cells
and autologous PBMC cultured with effector cell supernatants. PBMC of FIV-
infected cat 308 were divided into three groups. Open squares represent cells
stimulated with ConA for the first 3 days and then cultured in normal culture
medium. Closed squares represent effector cells stimulated with APC twice a
week for 21 days and then cultured for 4 days without APC. The supernatants of
effector cells were collected every 3 or 4 days and added to recipient autologous
cells. Triangles represent cells stimulated with ConA for the first 3 days and then
cultured with the supernatant of stimulated effector cells at a medium/superna-
tant ratio of 1:1 for 22 days. The supernatants from the three groups of cells were
collected every 3 or 4 days, and FIV replication was measured by a capsid antigen
ELISA.
TABLE 1. CTL and FIV-suppressive responses of uninfected and FIV-infected cats
Expt FIV status (negative [2]or positive [1]) Cat
CTL response
(% lysis)a
Virus-suppressive response
p24 ODb
%
Virus expressionc Viabilityd
1 2 OLQ4 1.5 0.86 6 0.10* 32 90.0 6 3.9
1 AUO2 8.8 0.43 6 0.09* 16 91.5 6 3.4
1 AUO3 3.0 0.92 6 0.14* 34 83.2 6 1.1
1 AZV2 4.7 0.38 6 0.06* 14 84.5 6 10.3
1 OLQ5 12.5 0.88 6 0.16* 33 88.9 6 1.5
1 308e NA 2.71 6 0.12 100 90.0 6 4.6
2 1 E238 50.0 3.77 6 0.24 117 83.3 6 3.5
1 E284 6.8 2.12 6 0.74 66 83.3 6 6.0
1 AWF1 6.0 0.44 6 0.08* 14 85.0 6 5.0
1 284f NA 3.22 6 0.16 100 86.0 6 2.0
a CTL responses were examined by determining the percent lysis of FIV-infected autologous target cells at E/T ratios of 100:1. Effector cells were stimulated for 14
days by inactivated autologous APC. NA, Not available.
b Cell culture supernatants collected from APC-stimulated effector cells for 1 week were added at a medium/supernatant ratio of 1:1 to FIV-PPR-infected cells (cat
308 PBMC) every 3 days. FIV expression was determined after 6 days of culturing by use of an FIV p24 antigen detection ELISA. Data represent the mean 6 standard
deviation for three experiments. Values marked by an asterisk were statistically different at a P value of ,0.05.
c Relative to virus expression of untreated control cells.
d Viable cells were counted by trypan blue exclusion and reported as the mean 6 standard deviation.
e These control cells (FIV-PPR-infected cat 308 PBMC) were cultured without effector cell supernatant.
f These control cells (FIV-PPR-infected cat 284 PBMC) were cultured without effector cell supernatant.
TABLE 2. Comparison of FIV-suppressive activities of
supernatants collected from antigen- and ConA-stimulated
PBMC of FIV-infected and uninfected cats
FIV
status Cat
Results for cell supernatants stimulated by:
Antigena ConAb
p24 ODc % Virusexpressiond p24 OD
c % Virus
expressiond
Negative AUS3 1.14 6 0.08* 31 3.62 6 0.06 110
OAE5 1.19 6 0.25* 32 2.77 6 0.29 84
OLM6 2.23 6 0.20* 61 3.66 6 0.13 111
OLQ4 2.36 6 0.50* 64 3.59 6 0.23 109
Positive AUO2 0.60 6 0.05* 16 3.34 6 0.28 102
AUO3 1.40 6 0.08* 38 3.75 6 0.05 114
AZV2 1.82 6 0.11* 49 3.04 6 0.30 92
OLQ5 1.34 6 0.11* 36 3.50 6 0.29 106
308e 3.69 6 0.13 100 3.29 6 0.22 100
a PBMC obtained from uninfected and FIV-infected cats were stimulated with
autologous, irradiated APC for 1 week. The collected supernatants from the
stimulated cells were added at a medium/supernatant ratio of 1:1 to FIV-PPR-
infected cat 308 PBMC.
b PBMC obtained from uninfected and FIV-infected cats were stimulated with
ConA (5 mg/ml) for 4 days. The collected supernatants from the stimulated cells
were added at a medium/supernatant ratio of 1:1 to FIV-PPR-infected cat 308
PBMC.
c FIV p24 antigen was measured by use of an ELISA after 6 days of culturing
with supernatants. Data represent the mean 6 standard deviation for three
separate experiments. Values marked by an asterisk were statistically different at
a P value of ,0.05.
d Relative to virus expression of control cells.
e These control cells (FIV-PPR-infected cat 308 PBMC) were cultured only
with medium.
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The effect of the anti-FIV factor(s) in the supernatants was
dose dependent. The effect of various concentrations of the
anti-FIV factor(s) on FIV-PPR replication was examined. The
supernatant of cat 306 effector cells was collected after 2 weeks
of APC stimulation and added at various concentrations (50,
25, 12.5, 6.25, and 0%) to acutely infected cat 308 PBMC (Fig.
5). The activity of the anti-FIV factor(s) was dose dependent.
Cells cultured with 50 and 25% supernatants showed 84 and
71% inhibition of FIV-PPR replication, respectively. However,
cells cultured with 12.5% supernatant did not suppress viral
expression at all. Interestingly, viral replication in cells cultured
with 6.25% supernatant was increased.
Cross-reactivity and cell specificity of the anti-FIV factor(s).
The cross-reactive suppression of the anti-FIV factor(s) was
examined with FIV-PPR and FIV-Pet. The supernatant col-
lected from FIV-PPR-infected cat PBMC which had been
stimulated with irradiated FIV-PPR-infected APC suppressed
viral replication in FIV-Pet-infected PBMC (Fig. 6A). There
was 96.3% inhibition of viral replication in supernatant-treated
cells compared to nontreated control cells. This result demon-
strated that the suppressive activity of the anti-FIV factor(s)
was not strain specific. The same supernatant containing the
anti-FIV factor(s) used in the experiment shown in Fig. 6A was
examined for the suppression of FIV-Pet infection in CrFK
cells (Fig. 6B). However, the anti-FIV factor(s) did not sup-
press FIV-Pet expression in infected CrFK cells. Therefore,
the anti-FIV factor(s) produced from APC-activated PBMC
suppressed the replication of FIV-PPR and FIV-Pet in PBMC
but not the replication of FIV-Pet in CrFK cells.
The anti-FIV factor(s) originated from CD81 T lympho-
cytes. In order to determine the phenotype of the T cells
producing the anti-FIV factor(s), CD41 or CD81 T cells were
depleted from PBMC stimulated for 7 days with APC. The
enriched CD81 or CD41 T cells were cultured for an addi-
tional 7 days with APC, and the culture supernatants were
collected. The supernatants were added to FIV-PPR-infected
cat 308 PBMC, and their suppressive activities were examined
after 12 days of culturing (Fig. 7). The infected cells cultured
with the supernatant of cat 306 CD81 T cells demonstrated
82.8% inhibition of viral replication, compared with the in-
fected control cells. The supernatant of cat 308 CD81 T cells
demonstrated 46.5% suppression of viral replication in in-
fected cells. However, no inhibition of FIV replication was
observed in cells cultured with the supernatant of 308 CD41 T
cells.
The soluble anti-FIV factor(s) shares suppressive activity
with human chemokine MIP-1a. It is known that several hu-
man chemokines have HIV-suppressive activity (6, 13). The
FIV-suppressive activity of the supernatant of stimulated cat
306 PBMC was compared with those of human recombinant
b-chemokines, MIP-1a, MIP-1b, and RANTES, and an a-che-
mokine, SDF-1a (Table 3). Human MIP-1a, as well as the cat
306 supernatant, suppressed FIV replication (P, ,0.05) in
FIV-PPR-infected cells. SDF-1a, even at a concentration of
2,000 ng/ml, did not significantly (P, .0.05) inhibit FIV-PPR
FIG. 5. Dose-dependent activity of the anti-FIV factor(s). Cat 308 PBMC
were acutely infected in vitro with FIV and cultured for 4 days with the super-
natants of APC-stimulated cat 306 effector cells at concentrations of 50, 25, 12.5,
6.25, and 0%. The supernatants were added to the recipient cells on days 0 and
2 of culturing. FIV replication in the collected supernatants was measured on day
4 by a capsid antigen ELISA. The data are representative of the mean 6
standard deviation for three different experiments.
FIG. 6. (A) Cross-reactivity of the anti-FIV factor(s). PBMC infected in vitro
with FIV-Pet for 10 days were cultured for 11 days with supernatant collected
from FIV-PPR-infected cat 306 PBMC (306 Sup) which had been stimulated
with autologous APC for 2 weeks. Control cells were cultured with complete
RPMI 1640. Supernatant and medium were added to the infected cells every 3
days. FIV replication determined by an FIV p24 ELISA for cells cultured with
supernatant was compared with that for control cells cultured without superna-
tant. The data are representative of three different experiments. (B) Cell spec-
ificity of the anti-FIV factor(s). Chronically FIV-Pet-infected CrFK cells (105/ml)
were cultured for 4 days with supernatant collected from FIV-PPR-infected cat
306 PBMC (306 Sup) which had been stimulated with autologous APC for 2
weeks. Control cells were cultured with complete DMEM. Supernatant and
medium were added to cells every 2 days. FIV replication determined by an FIV
capsid antigen ELISA for cells cultured with supernatant was compared with that
for control cells cultured without supernatant. The data are representative of
three separate experiments. Error bars in both panels indicate standard devia-
tions.
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replication. In a separate experiment, 500 ng of SDF-1a actu-
ally resulted in expression of FIV that was 130% that in un-
treated control cells (data not shown). The percent viabilities
of FIV-infected cells cultured with MIP-1a and cat 306 super-
natant, which were 91.2 and 92.0%, respectively, did not differ
from that of the control cells (P, .0.05). Therefore, it was
demonstrated that the FIV inhibition mediated by the anti-
FIV factor(s) produced from APC-stimulated feline PBMC
and human MIP-1a was noncytolytic.
DISCUSSION
Although, unlike HIV, FIV readily infects both CD41 and
CD81 T lymphocytes (9), CD41 cells have been reported to
have the greatest proviral burden in vivo in acutely FIV-in-
fected cats (14, 15). In contrast, reverse transcriptase activities
in the supernatants of cloned CD41 T cells were not neces-
sarily higher than those in CD81 T cells after in vitro infection
(9). In this study, it was found that CD41 T cells of one
FIV-infected cat produced more virus than autologous CD81
T cells. However, CD81 T cells of a second FIV-infected cat
produced more virus than CD41 T cells. Therefore, both feline
CD41 and CD81 T cells can be major reservoirs for FIV-PPR
in chronically infected cats.
Protective in vivo immune responses have been associated
with the presence of FIV-specific CTL (18, 45). FIV-specific
CTL could be induced from PBMC of infected cats by in vitro
stimulation with autologous APC, whereas no FIV-specific
CTL activities were observed in PBMC of uninfected cats
under the same stimulation conditions (3, 40). FIV-specific
CTL could contribute to the control of virus replication in vivo,
thus maintaining the clinically healthy state of FIV-infected
cats. In this study, APC-stimulated effector cells of FIV-in-
fected cats consistently demonstrated CTL activity. Although
the activity was often below 10%, the CTL response of infected
cats was consistently greater than the cytolytic response of
effector cells from uninfected cats.
The amount of viral replication in PBMC from infected cats
cocultured with APC was found to be significantly lower than
the amount of virus detected in mitogen-stimulated PBMC
from the same cats. These studies focused on the nature of this
apparent suppression of FIV infection. FIV replication in
PBMC cultured without APC stimulation was 10-fold higher
than that in antigen-stimulated effector cells. Therefore, a pop-
ulation of PBMC, some of which are CD81 T lymphocytes with
integrated FIV proviral DNA, produces viral particles in the
presence of mitogenic activation. However, in the presence of
virus-specific antigen stimulation, CD81 T lymphocytes may
develop unidentified antiviral activities that in themselves
would inhibit endogenous viral replication. In addition, it has
been shown that FIV-specific APC stimulation increases the
relative number of CD81 T cells (28). Likewise, we observed
that APC stimulation induced an increase in the numbers of
CD81 cells and a decrease in the numbers of CD41 cells (data
not shown).
CD81 T cells of HIV-infected patients suppressed HIV rep-
lication when they were added to CD81 T-cell-depleted
PBMC. It was suggested that this antiviral activity was noncy-
tolytic and mediated by a soluble factor (8, 47, 48). The CD81
T-cell-mediated noncytotoxic antiviral activity was also sug-
gested to correlate with the clinically healthy or uninfected
state of HIV-infected or HIV-exposed individuals (4, 27, 43).
CD81 T-cell-mediated suppression of HIV replication by
CD81 T cells obtained from HIV-uninfected human beings
and chimpanzees was also demonstrated (12, 25). Similarly, the
FIV-specific CD81 T-lymphocyte antiviral activity in infected
cats was also demonstrated by coculturing CD81 with FIV-
infected CD41 T or MYA-1 cells, reducing viral replication in
the infected cells (10, 19, 23). In the present study, the anti-
FIV factor(s) could be produced from both FIV-infected and
uninfected cat PBMC. The CD81 T lymphocytes did not re-
quire prior exposure to a specific antigen for the production of
an APC-inducible anti-FIV factor(s). These distinct functions
may represent distinct subsets of CD81 T lymphocytes. The
CTL responses of infected cats did not correlate with the level
of suppression mediated by the anti-FIV factor(s) observed for
each animal. In fact, whereas the APC-exposed PBMC of cats
E238 and E284 did not produce suppressive activity for FIV-
infected lymphocytes, E238 exhibited the most impressive CTL
FIG. 7. Production of the anti-FIV factor(s) from CD81 T cells. After 7 days
of stimulation of PBMC of FIV-infected cats 306 and 308 with APC, CD41 or
CD81 T cells were depleted by the panning method. Unbound CD81 or CD41
T cells were collected. The separated CD81 and CD41 T cells were stimulated
again with APC for 7 days, and the supernatants (Sup) were collected. FIV-
infected cat 308 PBMC were cultured with the supernatants from 306 CD81, 308
CD81, and 308 CD41 T cells for 12 days. The supernatants were added to the
recipient cells on days 0, 3, 6, and 9 of culturing. FIV replication was measured
on day 12 by an ELISA. The data are representative of two separate experiments.
TABLE 3. Comparison of FIV-suppressive activities of anti-FIV
factor(s)-containing supernatants and human chemokines
Treatment p24 ODa
%
Virus
expressionb Viability
c
MIP-1a 0.13 6 0.03* 48 91.2 6 4.6
MIP-1b 0.27 6 0.12 102 88.8 6 5.3
RANTES 0.24 6 0.07 89 93.5 6 5.1
SDF-1a 0.17 6 0.07 66 93.3 6 2.0
Cat 306 supernatant 0.07 6 0.01* 28 92.0 6 4.1
Control cellsd 0.26 6 0.05 100 87.5 6 1.6
a Determined by use of an FIV p24 antigen detection ELISA for cell culture
supernatants after FIV-PPR-infected cat 306 PBMC were cultured for 6 days
with human b-chemokines (MIP-1a, MIP-1b, and RANTES), a human a-che-
mokine (SDF-1a), and APC-stimulated effector cell supernatant (cat 306 super-
natant). The concentration of human MIP-1a, MIP-1b, and RANTES was 500
ng/ml, and that of human SDF-1a was 2,000 ng/ml. Cat 306 supernatant was
added at a medium/supernatant ratio of 1:1. Data represent the mean 6 stan-
dard deviation for three separate experiments. Values marked by an asterisk
were statistically different at a P value of ,0.05.
b Relative to virus expression of control cells.
c Viable cells were counted by trypan blue exclusion and reported as the
mean 6 standard deviation.
d Control cells (FIV-PPR-infected cat 306 PBMC) were cultured only with
medium.
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response of any cat infected with FIV-PPR that we have ex-
amined.
Only cats E238 and E284 failed to produce inducible sup-
pressive activity. Whereas all other cats in this study had ini-
tially been infected with either 50 or 250 50% tissue culture
infective doses of FIV-PPR, these cats received 1,250 50%
tissue culture infective doses. The pathogenesis may have been
more severe, because the transient central nervous system ill-
ness was more pronounced in these two cats (unpublished
data). It will be of interest to further evaluate differences
between these animals and those that readily produced the
suppressive activity.
Induction of the suppressive activity by T lymphocytes may
be the result of a direct interaction with APC or, alternatively,
the result of an indirect mechanism, such as the release of
cytokines by APC. The major difference between the suppres-
sive responses described in this study and most studies exam-
ining CD81 T-cell-mediated antiviral activity is that in this
study, supernatants containing the anti-FIV factor(s) were ob-
tained from APC-stimulated effector cells rather than from
nonspecific mitogen-stimulated cells. However, the soluble an-
ti-FIV dose-responsive factor(s) demonstrated in this study is
similar to the previously described CD81 T-cell-mediated anti-
HIV factor (8, 30). The anti-FIV factor(s) suppressed viral
replication without eliminating infected cells.
To date, several factors have been shown to inhibit lentivirus
replication. The chemokines RANTES, MIP-1a, MIP-1b,
MDC, and SDF-1a have been shown to inhibit HIV replication
(6, 13, 33), and IL-16 has been shown to suppress the replica-
tion of HIV and SIV (2). CAF, a CD81 T-lymphocyte product
that differs from IL-16 and the described chemokines, may be
closely related to the feline CD81 T-lymphocyte factor (24, 29,
30, 34). It was suggested that several antiviral factors, each with
distinct activity, could be involved in the suppression of virus
replication (38, 39).
The human b-chemokines RANTES, MIP-1a, MIP-1b, and
MCP-1 could not prevent FIV-Pet infection in CrFK cells or in
T lymphocytes (22). In the present study, we demonstrated the
suppression of FIV-PPR replication in feline PBMC by human
MIP-1a at a concentration of 500 ng/ml, but equivalent con-
centrations of the other b-chemokines tested did not suppress.
Although the a-chemokine SDF-1a seemed to suppress FIV
replication at a concentration of 2,000 ng/ml, the suppression
was not statistically significant (0.1 . P . 0.05). When 500 ng
of SDF-1a per ml was used with infected PBMC, FIV expres-
sion was actually increased rather than suppressed (data not
shown). Human SDF-1a has been shown to inhibit FIV-Pet
infection in CrFK cells but not in T-cell lines, depending on the
incubation conditions (22). Two FIV strains, FIV-PPR and
FIV-Pet, have 91% homology in their amino acid sequences;
however, they have distinct cell tropisms and replication kinet-
ics in feline PBMC (36). The anti-FIV factor(s) demonstrated
in this study could inhibit both FIV-PPR and FIV-Pet replica-
tion in PBMC. However, the FIV-suppressive factor(s) could
not suppress FIV-Pet replication in CrFK cells, suggesting cell
specificity. Therefore, the anti-FIV factor(s) seems to differ
fundamentally from SDF-1a.
The exact nature of the anti-FIV factor(s) produced by stim-
ulated feline PBMC and the factor-secreting mechanism re-
main to be further defined. One factor or a combination of
factors, either known or at present unidentified, could be re-
sponsible for inhibiting FIV replication in lymphocytes. Fur-
ther examination of the mechanism responsible for the induc-
tion of suppressive activity and the mechanism of viral
suppression could lead to a better understanding of the role of
CD81 T cells in viral pathogenesis.
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